Clinical trials: Hematological Neoplasm
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia
RATIONALE: Giving thalidomide together with prednisone and cyclophosphamide may lessen symptoms caused by myelofibrosis and myeloid metaplasia.
- Trial name
- NCT00445900
- Testing
- cyclophosphamide, prednisone, thalidomide
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Solid Tumors, Acute Myeloid Leukemia
A Study of PLX51107 in Advanced Malignancies
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced…
- Conditions
- Solid Tumors, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT02683395
- Testing
- PLX51107
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Plexxikon
Diffuse Large B-cell Lymphoma
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete response with first-line rituximab-chemotherapy
- Trial name
- PILLAR2 (NCT00790036)
- Testing
- Everolimus
- Where
- 202 sites in United States, Argentina and 32 more
- Volunteers
- 742 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART B (NCT05751044)
- Testing
- Dasatinib, Venetoclax, Dexamethasone
- Where
- 33 sites in Austria, Belgium and 12 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Hematological Malignancies, Regulatory T Cell Depletion
Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion
Since the discovery that Treg suppress anti-tumor immune responses, inhibiting their function has become a major challenge for the development of efficient immunotherapy for cancer.
- Conditions
- Hematological Malignancies, Regulatory T Cell Depletion, Relapse
- Trial name
- ILDTreg2 (NCT06180499)
- Testing
- T-reg depleted DLI
- Volunteers
- 27 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally.
- Conditions
- Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma
- Trial name
- NCT05415098
- Testing
- APG-5918
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Hematologic Malignancies
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
This study is an open-label randomized, prospectively and historically controlled trial of the safety and efficacy of a single ProHema-CB unit used as part of a double CB transplant following myeloablative or reduced intensity…
- Trial name
- NCT01627314
- Testing
- ProHema-CB, Untreated CB
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- Fate Therapeutics
Acute Leukemia, Myelodysplastic Syndrome
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant
- Trial name
- NCT07573111
- Testing
- QUAIL-100
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Laguna Biotherapeutics, Inc.
Hematological Malignancies
Rituximab for Prevention of Chronic GVHD
The purpose of this trial is to determine if administration of rituximab after allogeneic stem cell transplantation can reduce the incidence of chronic GVHD.
- Trial name
- NCT00379587
- Testing
- Rituximab, 375 mg/m2 RRituximab
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia
- Trial name
- NCT04191187
- Testing
- Fludarabine, Melphalan, Total Body Irradiation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell maturation antigen (BCMA).
- Trial name
- NCT02064387
- Testing
- GSK2857916
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Anemia, Graft Versus Host Disease
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Bone marrow that has been treated to remove certain white blood cells may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy, and may reduce the chance of developing…
- Conditions
- Anemia, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00003398
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Maryland, Baltimore
Chemotherapy Induced Oral Mucositis
Effect of Quercetin in Prevention and Treatment of Oral Mucositis
The study aims to evaluate the effect of Quercetin (a natural flavonoid) on prevention of and treatment of chemotherapy-induced oral mucositis in patients with blood malignancies.
- Trial name
- NCT01732393
- Testing
- oral quercetin capsules
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Mashhad University of Medical Sciences
Hematopoietic and Lymphoid Cell Neoplasm
Exercise Prehab in Older Adults With Hematologic Malignancies
This pilot trial studies a structured exercise program intervention in improving physical activity in older patients with hematologic malignancies undergoing cancer therapy.
- Trial name
- NCT02791737
- Testing
- Exercise Intervention, Laboratory Biomarker Analysis, Physical Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Malignancies, Hematologic
Pretransplant Evaluation by Supportive Care Team for Patients Undergoing HCT for Hematological Malignancies
This is a feasibility study of pre-transplant involvement of a palliative care provider in the setting of HCT. Although this is primarily a feasibility pilot, the investigators will explore how patients are affected by the…
- Trial name
- NCT02321345
- Testing
- Palliative Care Support
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Medical College of Wisconsin
Relapsed/Refractory Solid Tumors/Hematological Malignancies
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
A phase I, open-label, nonrandomized study to determine the PK profile of belinostat in patients with relapsed/refractory solid tumors or hematological malignancies in patients with renal impairment.
- Trial name
- NCT02679131
- Testing
- Belinostat
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Acrotech Biopharma Inc.
Hematologic Malignancies, Graft vs Host Disease
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
The proposed research study is to test the drug vorinostat, in a new use as an additional medication, with other standard treatments for the prevention of severe acute graft versus host disease (GVHD).
- Trial name
- NCT00810602
- Testing
- reduced intensity, related donor stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis)
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Pavan Reddy, MD
Pediatric Cancer, Hematologic Malignancies
Murottal as Adjunctive Intervention in Pediatric
This study aims to evaluate whether listening to the recitation of Surah Ar-Rahman (Murottal) before bedtime can help improve anxiety and sleep quality in hospitalized children with blood cancer.
- Conditions
- Pediatric Cancer, Hematologic Malignancies, Anxiety, Sleep Disturbances in Children
- Trial name
- NCT07861477
- Testing
- Murottal Intervention
- Where
- Indonesia
- Volunteers
- 20 people
- Sponsor
- Universitas Airlangga
Neutropenic Fever, Acute Lymphoblastic Leukemia
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
This clinical trial will compare use of ciprofloxacin and ceftazidime work in treating high-risk fever in children with hematological malignancies 1.
- Conditions
- Neutropenic Fever, Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, Non Hodgkin Lymphoma
- Trial name
- NCT07016165
- Testing
- Ceftazidime, Ciprofloxacin
- Where
- Indonesia
- Volunteers
- 120 people
- Sponsor
- Gadjah Mada University
Immunogenicity, Hematological Malignancies
Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies
Covid-19 is associated with a mortality rate of 33-37% in patients with hematological malignancies. At present, the anti-SARS-CoV-2 vaccination represents the most effective strategy for the prevention of Covid-19.
- Conditions
- Immunogenicity, Hematological Malignancies, Covid-19, Vaccine Response Impaired
- Trial name
- NCT04878822
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Ospedale di Circolo - Fondazione Macchi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.